Table 1.
Characteristics of NAP patients starting antiretroviral therapy from 2000 to 2014, by period of initiation
| Characteristic | Years | Years | Total | P-value |
|---|---|---|---|---|
| 2000–2007
n |
2008–2014
n |
n | ||
| Participants | 103,213 | 206,100 | 309,313 | |
| Male n(%) | 52,981 (51) | 110,409 (54) | 163,390 (53) | <0.001 |
| Median (IQR) age at ARV initiation (years) | 36 (32–41) | 37 (31–43) | 37 (31–43) | <0.001 |
| Median (IQR) years of follow-up | 7.5 (7.1–8.4) | 2.5 (1–4.5) | 4.2 (1.6–7.1) | <0.001 |
| Year of starting ART, n (%) | ||||
| 2000 | 395 (0.4) | 395 (0.1) | ||
| 2001 | 715 (0.7) | 715 (0.2) | ||
| 2002 | 2046 (2) | 2046 (1) | ||
| 2003 | 4260 (4) | 4260 (1) | ||
| 2004 | 8128 (8) | 8128 (3) | ||
| 2005 | 9702 (9) | 9702 (3) | ||
| 2006 | 13,513 (13) | 13,513 (4) | ||
| 2007 | 64,454 (62) | 64,454 (21) | ||
| 2008 | 30,451 (15) | 30,451 (10) | ||
| 2009 | 27,905 (14) | 27,905 (9) | ||
| 2010 | 29,241 (14) | 29,241 (9) | ||
| 2011 | 28,342 (14) | 28,342 (9) | ||
| 2012 | 32,238 (16) | 32,238 (10) | ||
| 2013 | 34,742 (17) | 34,742 (11) | ||
| 2014 | 23,181 (11) | 23,181 (7) | ||
| Partcipants with a CD4 cell count at ART initiation n (%) | 18,399 (18) | 137,484 (67) | 155,883 (50) | |
| Median (IQR) (cells/mm3) | 192 (69–371) | 115 (35–244) | 125 (37–257) | <0.001 |
| First regimen | <0.001 | |||
| NNRTI-based (all) | 98,736 (96) | 188,495 (91) | 287,231 (93) | |
| NVP-based | 81,087 (79) | 121,891 (59) | 202,978 (66) | |
| EFV-based | 17,649 (17) | 66,604 (32) | 84,253 (27) | |
| PI-based | 3223 (3) | 14,982 (7) | 18,205 (6) | |
| Other | 1254 (1) | 2623 (1) | 3877 (1) | |
| HIV clinical stage at baseline | <0.001 | |||
| Asymptomatic HIV | 23,531 (23) | 95,878 (47) | 119,409 (39) | |
| Symptomatic HIV | 24,368 (24) | 47,742 (23) | 72,110 (23) | |
| AIDS | 43,115 (42) | 58,714 (28) | 101,829 (33) | |
| Unknown | 12,199 (12) | 3766 (2) | 15,965 (5) |
ART: antiretroviral therapy; ARV antiretroviral; EFV: efavirenz; IQR: interquartile range; NNRTI: non-nucleoside reverse transcriptase inhibitors; NVP: nevirapine; PI: protease inhibitors.